FOXF2 suppresses the FOXC2-mediated epithelial-mesenchymal transition and multidrug resistance of basal-like breast cancer

Cancer Letters

Volumn 367, Issue 2, 2015, Pages 129-137

  Cai, Jun ^a   Tian, Ai Xian ^a   Wang, Qing Shan ^a   Kong, Peng Zhou ^a   Du, Xin ^a   Li, Xiao Qing ^a   Feng, Yu Mei ^a  

^a TIANJIN MEDICAL UNIVERSITY   (China)

Author keywords

Basal like breast cancer; Epithelial mesenchymal transition; FOXC2; FOXF2

Indexed keywords

CISPLATIN; EPIDERMAL GROWTH FACTOR RECEPTOR 2; EPIRUBICIN; FLUOROURACIL; FORKHEAD TRANSCRIPTION FACTOR; MESSENGER RNA; PACLITAXEL; TRANSCRIPTION FACTOR FOXC2; TRANSCRIPTION FACTOR FOXF2; UNCLASSIFIED DRUG; ANTINEOPLASTIC AGENT; FOXF2 PROTEIN, HUMAN; TUMOR MARKER;

ARTICLE; BASAL LIKE BREAST CANCER; BREAST CANCER CELL LINE; CANCER PROGNOSIS; CELL ADHESION; CELL INVASION; CELL MIGRATION; CONTROLLED STUDY; DISEASE FREE SURVIVAL; EPITHELIAL MESENCHYMAL TRANSITION; GENE EXPRESSION; HUMAN; HUMAN CELL; HUMAN TISSUE; MAJOR CLINICAL STUDY; MULTIDRUG RESISTANCE; PRIORITY JOURNAL; PROMOTER REGION; TRANSCRIPTION REGULATION; TRIPLE NEGATIVE BREAST CANCER; BREAST TUMOR; DOSE RESPONSE; DRUG EFFECTS; DRUG RESISTANCE; FEMALE; GENE EXPRESSION REGULATION; GENETIC TRANSCRIPTION; GENETIC TRANSFECTION; GENETICS; KAPLAN MEIER METHOD; MCF 7 CELL LINE; METABOLISM; MORTALITY; PATHOLOGY; PHENOTYPE; RNA INTERFERENCE; SIGNAL TRANSDUCTION; TIME;

ANTINEOPLASTIC AGENTS; BREAST NEOPLASMS; DISEASE-FREE SURVIVAL; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG RESISTANCE, MULTIPLE; DRUG RESISTANCE, NEOPLASM; EPITHELIAL-MESENCHYMAL TRANSITION; FEMALE; FORKHEAD TRANSCRIPTION FACTORS; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; KAPLAN-MEIER ESTIMATE; MCF-7 CELLS; PHENOTYPE; RNA INTERFERENCE; RNA, MESSENGER; SIGNAL TRANSDUCTION; TIME FACTORS; TRANSCRIPTION, GENETIC; TRANSFECTION; TRIPLE NEGATIVE BREAST NEOPLASMS; TUMOR MARKERS, BIOLOGICAL;

EID: 84939251769     PISSN: 03043835     EISSN: 18727980     Source Type: Journal    
DOI: 10.1016/j.canlet.2015.07.001     Document Type: Article

References (28)

1. Jemal A., Bray F., Center M.M., Ferlay J., Ward E., Forman D. Global cancer statistics. CA Cancer J. Clin 2011, 61:69-90.
2. Sorlie T., Perou C.M., Tibshirani R., Aas T., Geisler S., Johnsen H., et al. Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc. Natl. Acad. Sci. U.S.A. 2001, 98:10869-10874.
3. Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet 2005, 365:1687-1717. Early Breast Cancer Trialists' Collaborative Group (EBCTCG).
4. Cheang M.C., Voduc D., Bajdik C., Leung S., McKinney S., Chia S.K., et al. Basal-like breast cancer defined by five biomarkers has superior prognostic value than triple-negative phenotype. Clin. Cancer Res 2008, 14:1368-1376.
5. Kalluri R., Weinberg R.A. The basics of epithelial-mesenchymal transition. J. Clin. Invest 2009, 119:1420-1428.
6. Taube J.H., Herschkowitz J.I., Komurov K., Zhou A.Y., Gupta S., Yang J., et al. Core epithelial-to-mesenchymal transition interactome gene-expression signature is associated with claudin-low and metaplastic breast cancer subtypes. Proc. Natl. Acad. Sci. U.S.A. 2010, 107:15449-15454.
7. May C.D., Sphyris N., Evans K.W., Werden S.J., Guo W., Mani S.A. Epithelial-mesenchymal transition and cancer stem cells: a dangerously dynamic duo in breast cancer progression. Breast Cancer Res 2011, 13:202.
8. Mani S.A., Guo W., Liao M.J., Eaton E.N., Ayyanan A., Zhou A.Y., et al. The epithelial-mesenchymal transition generates cells with properties of stem cells. Cell 2008, 133:704-715.
9. Sarrio D., Franklin C.K., Mackay A., Reis-Filho J.S., Isacke C.M. Epithelial and mesenchymal subpopulations within normal basal breast cell lines exhibit distinct stem cell/progenitor properties. Stem Cells 2012, 30:292-303.
10. Myatt S.S., Lam E.W. The emerging roles of forkhead box (Fox) proteins in cancer. Nat. Rev. Cancer 2007, 7:847-859.
11. Wijchers P.J., Burbach J.P., Smidt M.P. In control of biology: of mice, men and Foxes. Biochem. J. 2006, 397:233-246.
12. Katoh M., Igarashi M., Fukuda H., Nakagama H. Cancer genetics and genomics of human FOX family genes. Cancer Lett 2013, 328:198-206.
13. Bernardo G.M., Bebek G., Ginther C.L., Sizemore S.T., Lozada K.L., Miedler J.D., et al. FOXA1 represses the molecular phenotype of basal breast cancer cells. Oncogene 2013, 32:554-563.
14. Mani S.A., Yang J., Brooks M., Schwaninger G., Zhou A., Miura N., et al. Mesenchyme Forkhead 1 (FOXC2) plays a key role in metastasis and is associated with aggressive basal-like breast cancers. Proc. Natl. Acad. Sci. U.S.A. 2007, 104:10069-10074.
15. Hollier B.G., Tinnirello A.A., Werden S.J., Evans K.W., Taube J.H., Sarkar T.R., et al. FOXC2 expression links epithelial-mesenchymal transition and stem cell properties in breast cancer. Cancer Res 2013, 73:1981-1992.
16. Aitola M., Carlsson P., Mahlapuu M., Enerback S., Pelto-Huikko M. Forkhead transcription factor FoxF2 is expressed in mesodermal tissues involved in epithelio-mesenchymal interactions. Dev. Dyn 2000, 218:136-149.
17. Kong P.Z., Yang F., Li L., Li X.Q., Feng Y.M. Decreased FOXF2 mRNA expression indicates early-onset metastasis and poor prognosis for breast cancer patients with histological grade II tumor. PLoS ONE 2013, 8:e61591.
18. Wang Q.S., Kong P.Z., Li X.Q., Yang F., Feng Y.M. FOXF2 deficiency promotes epithelial-mesenchymal transition and metastasis of basal-like breast cancer. Breast Cancer Res 2015, 17:30.
19. Yu Y., Xiao C.H., Tan L.D., Wang Q.S., Li X.Q., Feng Y.M. Cancer-associated fibroblasts induce epithelial-mesenchymal transition of breast cancer cells through paracrine TGF-beta signalling. Br. J. Cancer 2014, 110:724-732.
20. Takahashi S., Leiss M., Moser M., Ohashi T., Kitao T., Heckmann D., et al. The RGD motif in fibronectin is essential for development but dispensable for fibril assembly. J. Cell Biol 2007, 178:167-178.
21. Hollier B.G., Evans K., Mani S.A. The epithelial-to-mesenchymal transition and cancer stem cells: a coalition against cancer therapies. J. Mammary Gland Biol. Neoplasia 2009, 14:29-43.
22. Harburger D.S., Calderwood D.A. Integrin signalling at a glance. J. Cell Sci 2009, 122:159-163.
23. Li D.M., Feng Y.M. Signaling mechanism of cell adhesion molecules in breast cancer metastasis: potential therapeutic targets. Breast Cancer Res. Treat 2011, 128:7-21.
24. Akiyama S.K., Olden K., Yamada K.M. Fibronectin and integrins in invasion and metastasis. Cancer Metastasis Rev 1995, 14:173-189.
25. Hayashi H., Sano H., Seo S., Kume T. The Foxc2 transcription factor regulates angiogenesis via induction of integrin beta3 expression. J. Biol. Chem 2008, 283:23791-23800.
26. Rakha E.A., El-Rehim D.A., Paish C., Green A.R., Lee A.H., Robertson J.F., et al. Basal phenotype identifies a poor prognostic subgroup of breast cancer of clinical importance. Eur. J. Cancer 2006, 42:3149-3156.
27. Liedtke C., Mazouni C., Hess K.R., Andre F., Tordai A., Mejia J.A., et al. Response to neoadjuvant therapy and long-term survival in patients with triple-negative breast cancer. J. Clin. Oncol 2008, 26:1275-1281.
28. Neve R.M., Chin K., Fridlyand J., Yeh J., Baehner F.L., Fevr T., et al. A collection of breast cancer cell lines for the study of functionally distinct cancer subtypes. Cancer Cell 2006, 10:515-527.